Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis
Carcinoma, Renal Cell
Molecular Targeted Therapy
The use of targeted agents in the multimodal treatment of patients with RCC and brain metastasis was not associated with excessive neurologic adverse events. Clear cell histology, favorable MSKCC risk status, and solitary brain metastasis are associated with more favorable OS.